Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of Buy by Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Rating) has been assigned an average recommendation of “Buy” from the twelve ratings firms that are covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month price target among analysts […]

Related Keywords

Wellington ,New Zealand General ,New Zealand ,Blackrock ,Piper Sandler ,Morgan Stanley ,Securities Exchange Commission ,Deer Management Co ,Credit Suisse Group ,Zacks Investment Research ,Wellington Management Group ,Blackrock Inc ,Nasdaq ,Kymera Therapeutics Company Profile Get Rating ,Wells Fargo Company ,Kymera Therapeutics Inc ,Kymera Therapeutics ,Get Rating ,Investment Research ,Suisse Group ,Director Bvf Partners ,Exchange Commission ,Management Group ,State Street Corp ,Street Corp ,Therapeutics Company Profile ,Nasdaq Kymr ,Kymr ,Medical ,Ratings ,Consensus ,